# SARS-CoV-2 Persistence and the Gut Microbiota: New Insights into Long COVID Pathogenesis

## TL;DR

This paper explores how SARS-CoV-2 can persist in the gut, leading to chronic inflammation and gut microbiota changes that may cause long-term conditions like Long COVID and inflammatory bowel diseases.

## Contribution

The paper introduces new insights into the role of gut microbiota and persistent SARS-CoV-2 infection in the development of Long COVID and enteric disorders.

## Key findings

- SARS-CoV-2 persistence in the gastrointestinal tract is linked to Long COVID and chronic inflammation.
- Persistent infection may contribute to the development of Crohn’s disease and ulcerative colitis.
- Gut microbiota dysbiosis is a key factor in antiviral defense and gastrointestinal conditions.

## Abstract

In December 2019, the world experienced the emergence of a new virus, SARS-CoV-2, which caused the 2020 pandemic. SARS-CoV-2 causes COVID-19, primarily affecting the respiratory system, as well as the gastrointestinal tract. Remarkably, one in eight COVID-19 patients develops Long COVID, which is linked to SARS-CoV-2 persistence in the gastrointestinal tract, resulting in chronic inflammation and microbiota dysregulation. Given that gut microbiota dysbiosis plays a pivotal role in antiviral defense and gastrointestinal conditions, here we examine emerging evidence on how persistent SARS-CoV-2 infection may contribute to the aetiology of enteric disorders. In particular, we emphasise the intricate connection between chronic inflammation caused by persistent SARS-CoV-2 infection (e.g., irritable bowel syndrome and inflammatory bowel disease) and the possible development of diseases such as Crohn’s disease and ulcerative colitis.